title: HER2 status for prognosis and prediction of treatment efficacy in adenocarcinomas: a review.
abstract: The past few years have seen flourish new biologic parameters for cancer prognosis that are revolutionizing therapeutic strategies. HER-2 is in this perspective a striking example, as it is now a key element for the care of 15-20% of breast cancer. HER-2 overexpression has first been reported as a prognostic factor before its consideration as a main parameter to predict treatment efficacy. However, although HER-2 status is now also used as a prognostic factor for many cancers, its ability to predict the action of trastuzumab in these new contexts is much lower than in breast cancer. In this literature review, we aimed to discuss HER-2 overexpression as a prognostic factor and as a predictive parameter of treatment response in selected solid tumors with a focus on adenocarcinomas.
authors.affiliation: AP-HP, GH Henri Mondor, Department of Radiation Oncology and Henri Mondor Breast Center, University of Paris Est Créteil (UPEC), Créteil, France.
authors.forename: Constance
authors.initials: C
authors.lastname: Thibault
authors.forename: Wassim
authors.initials: W
authors.lastname: Khodari
authors.forename: Marie
authors.initials: M
authors.lastname: Lequoy
authors.forename: Joseph
authors.initials: J
authors.lastname: Gligorov
authors.forename: Yazid
authors.initials: Y
authors.lastname: Belkacémi
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000235:genetics* / Q000401:mortality; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D015870:Gene Expression; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000401:mortality; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics*; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases
keywords: ADCC; AROME; Adenocarcinomas; Cancers; EGFR; FISH; HAMA; HER-2; IHC; LVEF; NSCLC; Prediction of response; Prognostic; Trastuzumab; antibody-dependent cell-mediated cytotoxicity; epidermal growth factor; fluorescence in situ hybridization; human anti-murin immune response; immunohistochemical; left ventricular ejection fraction; non-small-cell lung cancer